/CVS%20Health%20Corp%20corporate%20office-by%20JHVEPhoto%20via%20iStock.jpg)
With a market cap of $80.4 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company headquartered in Woonsocket, Rhode Island. It operates through three main segments - Health Care Benefits; Health Services; and Pharmacy & Consumer Wellness, offering a wide range of health solutions including insurance, pharmacy benefit management, and retail pharmacy services.
Companies valued at $10 billion or more are generally considered "large-cap" stocks, and CVS Health fits this criterion perfectly. Serving diverse clients from individuals to government programs, CVS Health plays a key role in the U.S. healthcare ecosystem.
Despite this, shares of the Woonsocket, Rhode Island-based company have declined 11.8% from its 52-week high of $72.51. CVS stock has decreased 3.8% over the past three months, lagging behind the Nasdaq Composite’s ($NASX) 7.8% rise over the same time frame.
In the longer term, shares of CVS Health have risen 3.3% over the past 52 weeks, compared to NASX’s 14.5% return over the same time frame. However, CVS stock is up 42.1% on a YTD basis, outperforming NASX’s 1.6% gain.
The stock has been trading above its 200-day moving average since early February.
Shares of CVS Health rose 4.1% on May 1 after the company reported strong Q1 2025 results, with adjusted EPS of $2.25, up 71.8% year-over-year and beating the consensus estimate. Revenues grew 7% year-over-year to $94.6 billion, surpassing expectations, driven by solid performance across all segments, including an 11.1% increase in Pharmacy & Consumer Wellness and an 8% rise in Health Care Benefits. Additionally, CVS raised its full-year adjusted EPS guidance to $6 - $6.20.
Moreover, CVS Health stock has outperformed its rival UnitedHealth Group Incorporated (UNH). UNH stock has declined 38.2% over the past 52 weeks and 40.1% on a YTD basis.
Due to the stock’s strong performance on a YTD basis, analysts remain bullish on CVS Health. The stock has a consensus rating of “Strong Buy” from 23 analysts in coverage, and as of writing, CVS is trading below the mean price target of $79.14.
